Video Archives

Rationale for Involved Site SBRT-Enhanced Intermittent Androgen Deprivation Therapy in Nodal Oligorecurrent Prostate Cancer

Posted by Sean P. Collins MD, PhD | Sep 2024

Sean P. Collins, MD, PhD, discusses stereotactic body radiation therapy (SBRT) combined with intermittent androgen deprivation therapy (ADT) in managing nodal oligorecurrent prostate cancer. He emphasizes the evolving landscape of prostate cancer treatment, particularly in patients with limited nodal metastases, where traditional systemic approaches are being re-evaluated in favor of targeted and less toxic strategies.
Dr. Collins explores the clinical evidence supporting SBRT as a precise and effective modality that targets metastatic nodes while sparing surrounding healthy tissues. He underscores that when SBRT is combined with intermittent ADT, it provides a synergistic effect that not only controls localized disease but also allows for periodic withdrawal of ADT, thereby reducing the need for life-long hormone therapy.
Ultimately, Dr. Collins advocates for a paradigm shift toward more personalized and targeted management of nodal oligorecurrent prostate cancer. His insights provide a thoughtful analysis of the potential benefits of integrating SBRT and intermittent ADT.

BPH Mist Options: Rezum & Stents

Posted by Kevin C. Zorn, MD, FRCSC, FACS | Sep 2024

Kevin C. Zorn, MD, FACS, FRCSC, addresses the challenges and advancements in managing benign prostatic hyperplasia (BPH), focusing on minimally invasive surgical techniques. In this 17-minute presentation, he highlights the limitations of traditional treatments, such as transurethral resection of the prostate (TURP), and a growing demand for effective and less invasive alternative options.

Dr. Zorn explores the evolution of BPH treatments, discussing the importance of finding office-based, quick, and cost-effective solutions. He describes various less invasive technologies, including UroLift, Rezūm, and novel stent devices like iTind and Optilume.

Zorn underscores the variability in patient outcomes based on prostate anatomy and tissue composition, noting the importance of personalized treatment approaches. Moving towards a more tailored approach, similar to the precision seen in prostate cancer management, considers prostate size and tissue composition.

Laser Selection for HoLEP

Posted by Pierluigi Bove, MD | Sep 2024

Pierluigi Bove, MD, discusses the selection of lasers for Holmium laser enucleation of the prostate (HoLEP), focusing on the evolution and advancements in laser technology since 1995. In this 9-minute presentation, Bove emphasizes that the choice of laser depends on personal preference and experience, technical features, and economic considerations. Dr. Bove considers the Holmium laser the gold standard for BPH surgery due to its versatility in treating various prostate sizes and conditions such as stones.

The discussion then shifts to a comparison between the traditional Holmium laser and newer technologies like the Thulium laser with pulse modulation. Bove presents evidence suggesting that the MOSES effect, available with Holmium lasers, can improve intraoperative hemostasis, shorten operative time, and enhance outcomes.

Ultimately, the selection of the appropriate laser for prostate enucleation depends on various factors, including the surgeon’s familiarity with the technology, the type of procedure, and resource availability.

IFRUU Lectureship: Development of a Simple-Minded and User-friendly Classification System Applicable to All Types of Lower Urinary Tract Dysfunction

Posted by Alan J. Wein, MD, PhD (hon), FACS | Aug 2024

Alan J. Wein, MD, PhD (hon), FACS, discusses a simplified and user-friendly classification system for lower urinary tract dysfunction (LUTD), which can be applied to both neurogenic and non-neurogenic conditions. In this 15-minute presentation, he acknowledges the contributions of earlier researchers and emphasizes the utility of this classification system as a guide for diagnosis and management.

The proposed system divides LUTD into two main categories: failure to store and failure to empty, with further subdivisions based on bladder or outlet dysfunction. The system is designed to be practical and applicable to various clinical scenarios. The system simplifies diagnosis and offers a logical framework for treatment options.

MRI-Invisible Prostate Cancer and Use of Biomarkers to Identify Potential Candidates

Posted by Priya N. Werahera, PhD | Aug 2024

Priya N. Werahera, PhD, discusses the challenges of MRI-invisible prostate cancer and biomarkers in prostate cancer diagnosis and treatment. His discussion highlights the limitations of current imaging techniques and the approaches being developed to overcome these obstacles.
Dr. Werahera begins by addressing the inherent difficulties in detecting prostate cancer lesions that evade MRI visibility. He emphasizes the role of biomarkers, which can reveal the presence of cancerous changes even when imaging results appear normal, as a complementary tool to imaging techniques.
By combining biomarker analysis with existing imaging techniques, clinicians can achieve a higher diagnostic yield and better tailor treatment strategies to individual patients. Dr. Werahera calls for collaborative efforts to validate and standardize biomarker use, ensuring their reliability and accessibility in routine clinical practice.